541 related articles for article (PubMed ID: 26471512)
21. Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in
Haseeb A; Abourehab MAS; Almalki WA; Almontashri AM; Bajawi SA; Aljoaid AM; Alsahabi BM; Algethamy M; AlQarni A; Iqbal MS; Mutlaq A; Alghamdi S; Elrggal ME; Saleem Z; Radwan RM; Mahrous AJ; Faidah HS
Int J Environ Res Public Health; 2022 Feb; 19(5):. PubMed ID: 35270525
[TBL] [Abstract][Full Text] [Related]
22. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.
Nickel P; Schürmann M; Albrecht H; Schindler R; Budde K; Westhoff T; Millward J; Suttorp N; Reinke P; Schürmann D
Infection; 2014 Dec; 42(6):981-9. PubMed ID: 25168263
[TBL] [Abstract][Full Text] [Related]
23. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice.
Lobo ML; Esteves F; de Sousa B; Cardoso F; Cushion MT; Antunes F; Matos O
PLoS One; 2013; 8(8):e70619. PubMed ID: 23940606
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C; Katergi K; Sorin M; Rjeily MB; Butler-Laporte G; McDonald EG; Lee TC
Clin Microbiol Infect; 2024 Jul; 30(7):866-876. PubMed ID: 38583518
[TBL] [Abstract][Full Text] [Related]
26. Renal Insufficiency in Concert with Renin-angiotensin-aldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low-dose Trimethoprim-sulfamethoxazole in Adults.
Higashioka K; Niiro H; Yoshida K; Oryoji K; Kamada K; Mizuki S; Yokota E
Intern Med; 2016; 55(5):467-71. PubMed ID: 26935365
[TBL] [Abstract][Full Text] [Related]
27. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.
Park JW; Curtis JR; Moon J; Song YW; Kim S; Lee EB
Ann Rheum Dis; 2018 May; 77(5):644-649. PubMed ID: 29092853
[TBL] [Abstract][Full Text] [Related]
29. Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.
Nielsen TL; Jensen BN; Nelsing S; Mathiesen LR; Skinhøj P; Nielsen JO
Scand J Infect Dis; 1995; 27(3):217-20. PubMed ID: 8539544
[TBL] [Abstract][Full Text] [Related]
30. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole.
Chen PY; Yu CJ; Chien JY; Hsueh PR
Int J Antimicrob Agents; 2020 Jan; 55(1):105820. PubMed ID: 31622654
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness and safety of low dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta-analysis.
Tritle BJ; Hejazi AA; Timbrook TT
Transpl Infect Dis; 2021 Dec; 23(6):e13737. PubMed ID: 34553814
[TBL] [Abstract][Full Text] [Related]
32. Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology.
Kokubu H; Kato T; Nishikawa J; Tanaka T; Fujimoto N
J Dermatol; 2021 Apr; 48(4):542-546. PubMed ID: 33492693
[TBL] [Abstract][Full Text] [Related]
33. Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study.
Jacobo-Vargas TB; Báez-Saldaña R; Cruz-Hervert LP; Fortoul TI; Ahumada-Topete VH; Rodríguez-Ganén O; Vega-Barrientos RS
PLoS One; 2023; 18(5):e0285541. PubMed ID: 37167312
[TBL] [Abstract][Full Text] [Related]
34. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
35. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
[TBL] [Abstract][Full Text] [Related]
36. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
[TBL] [Abstract][Full Text] [Related]
37. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
[TBL] [Abstract][Full Text] [Related]
38. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.
Para MF; Finkelstein D; Becker S; Dohn M; Walawander A; Black JR
J Acquir Immune Defic Syndr; 2000 Aug; 24(4):337-43. PubMed ID: 11015150
[TBL] [Abstract][Full Text] [Related]
39. Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.
Ye WL; Tang N; Wen YB; Li H; Li MX; Du B; Li XM
Int Urol Nephrol; 2016 Nov; 48(11):1863-1871. PubMed ID: 27351666
[TBL] [Abstract][Full Text] [Related]
40. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia.
Levinsen M; Shabaneh D; Bohnstedt C; Harila-Saari A; Jonsson OG; Kanerva J; Lindblom A; Lund B; Andersen EW; Schmiegelow K;
Eur J Haematol; 2012 Jan; 88(1):78-86. PubMed ID: 21854453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
